Your browser doesn't support javascript.
loading
Methylome Variation Predicts Exemestane Resistance in Advanced ER+ Breast Cancer.
Liu, Xiao-Ran; Zhang, Ru-Yan; Gong, Hao; Rugo, Hope S; Chen, Ling-Bo; Fu, Yuan; Che, Jian-Wei; Tie, Jian; Shao, Bin; Wan, Feng-Ling; Kong, Wei-Yao; Song, Guo-Hong; Jiang, Han-Fang; Xu, Guo-Bing; Li, Hui-Ping.
Afiliação
  • Liu XR; Department of Breast Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
  • Zhang RY; The authors contributed eually to the article.
  • Gong H; Department of Breast Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
  • Rugo HS; The authors contributed eually to the article.
  • Chen LB; M3 Genomics, Inc, Guangzhou, Guangdong, China.
  • Fu Y; The authors contributed eually to the article.
  • Che JW; University of California San Francisco Helen Diller Family Comprehensive Cancer Center, CA, USA.
  • Tie J; M3 Genomics, Inc, Guangzhou, Guangdong, China.
  • Shao B; M3 Genomics, Inc, Guangzhou, Guangdong, China.
  • Wan FL; M3 Genomics, Inc, Guangzhou, Guangdong, China.
  • Kong WY; Life Healthcare Group Ltd, Beijing, China.
  • Song GH; Department of Breast Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
  • Jiang HF; Department of Breast Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
  • Xu GB; Department of Breast Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
  • Li HP; Department of Breast Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
Technol Cancer Res Treat ; 19: 1533033819896331, 2020.
Article em En | MEDLINE | ID: mdl-32129154
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Resistencia a Medicamentos Antineoplásicos / Receptor alfa de Estrogênio / DNA Tumoral Circulante / Epigenoma / Androstadienos Idioma: En Ano de publicação: 2020 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Resistencia a Medicamentos Antineoplásicos / Receptor alfa de Estrogênio / DNA Tumoral Circulante / Epigenoma / Androstadienos Idioma: En Ano de publicação: 2020 Tipo de documento: Article País de afiliação: China